TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10868348
Drug: Brief individual
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief individual counseling and weekly newsletters (intervention)
Study: 3935013
Drug: Education program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Education program regarding asthma and asthma medications during four monthly visits
Study: 22906794
Drug: Experimental arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Experimental arm (n = 18) - shown detailed PSG data, including graphic data from PSG prior to prescription of CPAP
Study: 20189492
Drug: Investigational hepatitis
Normalized name: hepatitis nosodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational hepatitis B vaccine (spHB), 10 microg HBsAg/dose for 10-15 years age group; 20 microg HBsAg/dose for 16-45 years age group, administered in a 0, 1, 6 month schedule.
Study: 20189492
Drug: Licensed control
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Licensed control vaccine (Engerix B), administered in a 0, 1, 6 month schedule.
Study: 10372701
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human GH (rhGH) treatment; mean dosage 1.0 U/day for men and 1.9 U/day for women (P < 0.01)
Study: 10372701
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human GH (rhGH) treatment
Study: 1941495
Drug: CPC mouthrinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPC mouthrinse used as an adjunct to oral hygiene before toothbrushing
Study: 1941495
Drug: Placebo mouthrinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo mouthrinse used as an adjunct to oral hygiene before toothbrushing
Study: 25809373
Drug: Edoxaban (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxaban (60 mg for 3 months or 30 mg with increased exposure factors) + Aspirin (100 mg/d for 6 months)
Study: 25809373
Drug: Clopidogrel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (75 mg/d for 3 months) + Aspirin (100 mg/d for 6 months)
Study: 24010849
Drug: Study Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study Group (SG) - hemodynamic therapy guided by pulse pressure variation, cardiac index trending, and mean arterial pressure.
Study: 24010849
Drug: Control Group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control Group (CG) - hemodynamic therapy at the discretion of the treating anesthesiologist.
Study: 21504240
Drug: Budesonide/formoterol added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol added to tiotropium (Symbicort® Turbuhaler® 320/9 μg twice daily + tiotropium 18 μg daily)
Study: 21504240
Drug: Placebo added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo added to tiotropium (tiotropium 18 μg daily)
Study: 11544424
Drug: Daclizumab (Zenapax®,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daclizumab (Zenapax®, Roche Pharmaceuticals)
Study: 8433235
Drug: Maltodextrin-containing oral
Normalized name: Maltodextrin
DrugBank: Maltodextrin (DB12583)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maltodextrin-containing oral rehydration solution
Study: 6115808
Drug: LH-RH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: LH-RH treatment
Study: 25335387
Drug: Basic therapy
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic therapy without magnesium deficiency correction
Study: 23720246
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation (ibuprofen sustained-release)
Study: 23720246
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation (ibuprofen sustained-release)
Study: 10499756
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine (30 microg/kg followed by 3 microg/kg/h for 3 days)
Study: 10499756
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine (0.05-0.1 mg/kg intraoperatively, followed by 0.02 mg/kg doses postoperatively)
Study: 10499756
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (Epidural and Intravenous)
Study: 8560681
Drug: Bicalutamide 50
Normalized name: bicalutamide 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicalutamide 50 mg monotherapy
Study: 8560681
Drug: Bicalutamide 50
Normalized name: bicalutamide 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicalutamide 50 mg plus LHRH-A
Study: 30474791
Drug: IV ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV ibuprofen (800 mg)
Study: 30321520
Drug: IV acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV acetaminophen (1000 mg)
Study: 31012040
Drug: Control (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (100 ml saline solution)
Study: 31442441
Drug: Lactic-acid-containing diaphragm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactic-acid-containing diaphragm gel (Contragel®)
Study: 31442441
Drug: Hydroxyethylcellulose (HEC)
DrugBank: Hydroxyethyl cellulose (DB11602)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyethylcellulose (HEC) universal placebo gel
Study: 28363270
Drug: Cortisone Injections
Normalized name: cortisone Injectable Product
DrugBank: Cortisone (DB14681)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortisone Injections
Study: 31152334
Drug: Internet-delivered cognitive
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-delivered cognitive behavioral therapy for insomnia (CBT-I)
Study: 12560782
Drug: Piperacillin/tazobactam 3.375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin/tazobactam 3.375 g every 6 hours
Study: 8807592
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human growth hormone (rhGH) 5 mg/day s.c during treatment period (Tx) for 7 days
Study: 8807592
Drug: Post-treatment period
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Post-treatment period (PostGH) after discontinuation of rhGH
Study: 6094868
Drug: SBT/CPZ at
Approvals — FDA: no, EMA: no, PMDA: no
Description: SBT/CPZ at 20 mg/kg
Study: 6094868
Drug: SBT/CPZ at
Approvals — FDA: no, EMA: no, PMDA: no
Description: SBT/CPZ at 40 mg/kg
Study: 30325529
Drug: Intravenous paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous paracetamol for four days
Study: 29924745
Drug: Testosterone treatment
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone treatment (TEX, 100 mg·wk)
Study: 29924745
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (PEX)
Study: 26432791
Drug: Pavlik harness
Normalized name: HARNESS,PROREN UNDERGARMENT 2XL/3XL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pavlik harness treatment (group I: start within 10 days, group II: 11 days to 3 weeks, group III: after 4 weeks)
Study: 7767393
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of 250iu of anti-D Ig given at 28 and 34 weeks gestation
Study: 2310093
Drug: Amiloride inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiloride inhalation (10(‐3) M)
Study: 2310093
Drug: Amiloride inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiloride inhalation (2 times a day for 3 weeks)
Study: 2310093
Drug: Amiloride inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiloride inhalation
Study: 466843
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group (n = 8)
Study: 466843
Drug: Non-treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-treatment group (n = 10)
Study: 25994910
Drug: Standard BFM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard BFM therapy
Study: 25994910
Drug: Extended, usually
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended, usually more intensive experimental treatment
Study: 19048458
Drug: GW9662 (PPARgamma
Approvals — FDA: no, EMA: no, PMDA: no
Description: GW9662 (PPARgamma antagonist) with benzbromarone
Study: 19048458
Drug: GW9662 (PPARgamma
Approvals — FDA: no, EMA: no, PMDA: no
Description: GW9662 (PPARgamma antagonist) with pioglitazone
Study: 16889452
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Sertraline and HRT
Study: 11715490
Drug: E1 group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: E1 group (esmolol 1 mg/kg)
Study: 11715490
Drug: E2 group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2 group (esmolol 2 mg/kg)
Study: 26246241
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (100,000 IU followed by 4,000 IU daily for 16 weeks)
Study: 26246241
Drug: Placebo (identical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (identical capsules for 16 weeks)
Study: 18563688
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy with pemetrexed and cisplatin
Study: 18563688
Drug: Chemotherapy in
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy in pretreated patients
Study: 16630771
Drug: Orlistat (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orlistat (120 mg 3 times daily for 6 months)
Study: 12649866
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion titrated to a Bispectral Index near 80
Study: 12649866
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion titrated to a Bispectral Index near 60
Study: 7782484
Drug: Sertraline, 100
Normalized name: Sertraline, 100 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline, 100 mg
Study: 7782484
Drug: Sertraline, 200
Normalized name: Sertraline, 200 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline, 200 mg
Study: 7782484
Drug: Alprazolam, 1
Normalized name: Alprazolam, 1 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam, 1 mg
Study: 7782484
Drug: Dextroamphetamine, 10
Normalized name: Amphetamine-Dextroamphetamine, 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextroamphetamine, 10 mg
Study: 31465115
Drug: Single-injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-injection
Study: 22537421
Drug: Target hemoglobin
Normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Target hemoglobin level of 13.5 g/dL
Study: 22537421
Drug: Target hemoglobin
Normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Target hemoglobin level of 11.3 g/dL
Study: 19666395
Drug: High-dose N-acetylcysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose N-acetylcysteine (2800 mg/daily)
Study: 19666395
Drug: Low-dose N-acetylcysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose N-acetylcysteine (700 mg/daily)
Study: 17490437
Drug: Open irrigation
Normalized name: BOTTLE OPENER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open irrigation tip (OIT) technology; temperature and power set at 50 degrees and 50 W, saline pump flow rate of 30 mL/min
Study: 12010358
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy with adherence
Study: 12010358
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy with non-adherence
Study: 12010358
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy with adherence and nadir below limit
Study: 12010358
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy with adherence and nadir above limit
Study: 9820445
Drug: 1.1% amino
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.1% amino acid peritoneal dialysis solution (DAA)
Study: 27497779
Drug: NSAID (Ibuprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSAID (Ibuprofen 1800mg/day)
Study: 27497779
Drug: Healthy controls
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy controls (CRP<1mg/l)
Study: 25600772
Drug: CHO/HAA (CHO
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO/HAA (CHO + 13 g AA)
Study: 25600772
Drug: CHO/LAA (CHO
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO/LAA (CHO + 6.5 g AA)
Study: 25600772
Drug: CHO (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO (1.2 g/kg body weight)
Study: 23745309
Drug: 0.5-hour infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5-hour infusion of 0.5 g every six hours for 24 hours
Study: 23745309
Drug: 2-hour infusion
Normalized name: Interleukin-2/diptheria toxin fusion protein
DrugBank: Denileukin diftitox (DB00004)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2-hour infusion of 0.5 g every six hours for 24 hours
Study: 23745309
Drug: 2-hour infusion
Normalized name: Interleukin-2/diptheria toxin fusion protein
DrugBank: Denileukin diftitox (DB00004)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2-hour infusion of 1 g every six hours for 24 hours
Study: 21420732
Drug: Azacitidine 50
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azacitidine 50 mg/m² thrice weekly for 2 weeks every 4 weeks
Study: 21420732
Drug: Weekly erythropoietin
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly erythropoietin (in 7 patients)
Study: 19335843
Drug: Biologic agents
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biologic agents (Tumor necrosis factor inhibitors, Alemtuzumab, Rituximab)
Study: 19335843
Drug: Optimal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal therapy
Study: 15283740
Drug: Antidepressant Compliance
Normalized name: ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Antidepressant Compliance Questionnaire (ADCQ)
Study: 9313060
Drug: Ciprofloxacin 100
Normalized name: ciprofloxacin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 100 mg twice a day for 3 days
Study: 9313060
Drug: Cotrimoxazol 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cotrimoxazol 8 mg and pipemidic acid 100 mg administered twice a day (control group)
Study: 8497669
Drug: All solutions
Normalized name: ALCOHOL 0.57 mL in 1 mL / IODINE 0.06 g in 1 mL / POTASSIUM IODIDE 0.05 g in 1 mL / BORIC ACID 0.01 g in 1 mL / SODIUM BORATE 0.002 g in 1 mL TOPICAL LINIMENT [Ball Solutions]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All solutions
Study: 24295873
Drug: Emtricitabine/Tenofovir combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emtricitabine/Tenofovir combination therapy
Study: 24295873
Drug: Tenofovir monotherapy
Normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tenofovir monotherapy
Study: 22654006
Drug: IBV Valves
Normalized name: AmproMed for Calves
Approvals — FDA: no, EMA: no, PMDA: no
Description: IBV Valves (treatment group)
Study: 18487900
Drug: Psychosocial support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychosocial support therapy (Control)
Study: 10621925
Drug: Vinorelbine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinorelbine (30 mg/m2 on day 1 and day 8) and Cisplatin (100 mg/m2 on day 1) administered every three weeks
Study: 28913735
Drug: Tazarotene 0.1%
Normalized name: TAZAROTENE 0.1% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tazarotene 0.1% plus Clindamycin 1% gel
Study: 28913735
Drug: Adapalene 0.1%
Normalized name: ADAPALENE 0.1% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adapalene 0.1% plus Clindamycin 1% gel
Study: 24451122
Drug: Daclatasvir 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daclatasvir 10 mg with peginterferon alfa-2b/ribavirin
Study: 24451122
Drug: Daclatasvir 60
Normalized name: daclatasvir 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daclatasvir 60 mg with peginterferon alfa-2b/ribavirin
Study: 24451122
Drug: Daclatasvir 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daclatasvir 10 mg for prior non-responders
Study: 24451122
Drug: Daclatasvir 60
Normalized name: daclatasvir 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daclatasvir 60 mg for prior non-responders
Study: 22835054
Drug: Thrombolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic therapy (TG)
Study: 22835054
Drug: Without thrombolytic
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Without thrombolytic therapy (WTG)
Study: 22835054
Drug: Thrombolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic therapy (TG) and Without thrombolytic therapy (WTG)
Study: 19378646
Drug: Multidimensional Family
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidimensional Family Therapy HIV/STD risk-reduction intervention (MDFT-HIV/STD)
Study: 17412790
Drug: Oral glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose supplementation (G)
Study: 15054020
Drug: Housing First
Approvals — FDA: no, EMA: no, PMDA: no
Description: Housing First program (immediate housing without treatment prerequisites)
Study: 15054020
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (housing contingent on treatment and sobriety)
Study: 9462187
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (NO) for 72 hours
Study: 9462187
Drug: Dexamethasone (0.5‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (0.5‐1 mg/kg/day intravenous for 6 days)
Study: 9462187
Drug: Both inhaled
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both inhaled NO and dexamethasone
Study: 7949804
Drug: 0.5 IU/kg/week
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 IU/kg/week of recombinant human growth hormone for over one year
Study: 2896219
Drug: Three-vial system
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-vial system (buffered glycerol saline, Cary‐Blair medium with campylobacter antibodies, and polyvinyl alcohol fixative)
Study: 9989684
Drug: Test supplement
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test supplement
Study: 23988010
Drug: Moderate alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moderate alcohol intake (5 to 15 g/day)
Study: 17159759
Drug: Lidocaine 1
Normalized name: lidocaine 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 1 mL of 1% (10 mg) added to 100 mg of propofol
Study: 17037821
Drug: Tianeptine (37.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tianeptine (37.5 mg/day)
Study: 9593759
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution (154 mmol liter-1 NaCl)
Study: 8005273
Drug: Endometrial priming
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endometrial priming with oral micronized E2, 4 mg/d for 14 days; Progesterone replacement IM P in oil, 50 mg/d for 14 days.
Study: 2680288
Drug: Bezafibrate (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bezafibrate (200 mg twice or 3 times a day)
Study: 2680288
Drug: Probucol (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probucol (500 mg twice a day)
Study: 30898253
Drug: Sirolimus-coated balloon
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus-coated balloon (SeQuent SCB, 4 μg/mm2)
Study: 30898253
Drug: Paclitaxel-coated balloon
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel-coated balloon (SeQuent Please Neo, 3 μg/mm2)
Study: 27189694
Drug: 6-mercaptopurine (6MP)
Normalized name: 6-Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6-mercaptopurine (6MP) medication adherence
Study: 27189694
Drug: Behavioral adherence
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral adherence measures (e.g., electronic monitoring)
Study: 19372653
Drug: Terutroban 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terutroban 30 mg/day
Study: 15353532
Drug: Galantamine hydrobromide
Normalized name: Galantamine Hydrobromide
DrugBank: Galantamine (DB00674)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Galantamine hydrobromide 2.5 mg
Study: 15353532
Drug: Galantamine hydrobromide
Normalized name: Galantamine Hydrobromide
DrugBank: Galantamine (DB00674)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Galantamine hydrobromide 5.0 mg
Study: 15353532
Drug: Galantamine hydrobromide
Normalized name: Galantamine Hydrobromide
DrugBank: Galantamine (DB00674)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Galantamine hydrobromide 7.5 mg
Study: 15353532
Drug: Galantamine hydrobromide
Normalized name: Galantamine Hydrobromide
DrugBank: Galantamine (DB00674)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Galantamine hydrobromide 10 mg
Study: 2605069
Drug: Cimetidine 1600
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetidine 1600 mg orally before anaesthesia
Study: 2605069
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets before anaesthesia
Study: 16151033
Drug: Clopidogrel with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel with aspirin (C+ASA)
Study: 7741782
Drug: Amoxicillin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin (250 mg) plus bromhexine (8 mg) (Drug AB)
Study: 24154820
Drug: Prosure (specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prosure (specific supplement enriched with n-3 polyunsaturated fatty acids, fiber, proteins, and electrolytes)
Study: 24154820
Drug: Standard-Isosource (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-Isosource (standard supplement)